{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:22:12Z","timestamp":1784247732800,"version":"3.55.0"},"reference-count":142,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In recent years, the onco-nephrology field has acquired a relevant role in internal medicine due to the growing number of cases of renal dysfunction that have been observed in cancer patients. This clinical complication can be induced by the tumor itself (for example, due to obstructive phenomena affecting the excretory tract or by neoplastic dissemination) or by chemotherapy, as it is potentially nephrotoxic. Kidney damage can manifest as acute kidney injury or represent a worsening of pre-existing chronic kidney disease. In cancer patients, physicians should try to set preventive strategies to safeguard the renal function, avoiding the concomitant use of nephrotoxic drugs, personalizing the dose of chemotherapy according to the glomerular filtration rate (GFR) and using an appropriate hydration therapy in combination with nephroprotective compounds. To prevent renal dysfunction, a new possible tool useful in the field of onco-nephrology would be the development of a personalized algorithm for the patient based on body composition parameters, gender, nutritional status, GFR and genetic polymorphisms.<\/jats:p>","DOI":"10.3390\/cancers15082254","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T01:35:00Z","timestamp":1681349700000},"page":"2254","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1310-3730","authenticated-orcid":false,"given":"Annalisa","family":"Noce","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Nephrology and Dialysis Unit, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-2086","authenticated-orcid":false,"given":"Giulia","family":"Marrone","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8118-1330","authenticated-orcid":false,"given":"Manuela","family":"Di Lauro","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0132-386X","authenticated-orcid":false,"given":"Anna Paola","family":"Mitterhofer","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Nephrology and Dialysis Unit, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e8","family":"Ceravolo","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7671-0015","authenticated-orcid":false,"given":"Nicola","family":"Di Daniele","sequence":"additional","affiliation":[{"name":"Fondazione Leonardo per le Scienze Mediche Onlus, Policlinico Abano, 35031 Abano Terme, Italy"},{"name":"Department of Systems Medicine, Section of Endocrinology and Metabolic Diseases, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7659-5392","authenticated-orcid":false,"given":"Guglielmo","family":"Manenti","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Interventional Radiology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6524-4493","authenticated-orcid":false,"given":"Antonino","family":"De Lorenzo","sequence":"additional","affiliation":[{"name":"Section of Clinical Nutrition and Nutrigenomic, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000517695","article-title":"Onconephrology: A New Challenge for the Nephrologist","volume":"199","author":"Fofi","year":"2021","journal-title":"Contrib. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3322\/caac.21636","article-title":"Onconephrology: The intersections between the kidney and cancer","volume":"71","author":"Rosner","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nefroe.2018.10.016","article-title":"Onco-Nephrology: Cancer, chemotherapy and kidney","volume":"39","author":"Macia","year":"2019","journal-title":"Nefrologia (Engl. Ed.)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e000091","DOI":"10.1136\/esmoopen-2016-000091","article-title":"Renal insufficiency and cancer treatments","volume":"1","author":"Janus","year":"2016","journal-title":"ESMO Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Oudard","year":"2007","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9559","DOI":"10.1200\/jco.2009.27.15_suppl.9559","article-title":"Prevalence of renal insufficiency in cancer patients: Data from the IRMA-2 study","volume":"27","author":"Janus","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.23876\/j.krcp.19.042","article-title":"Acute kidney injury in the patient with cancer","volume":"38","author":"Rosner","year":"2019","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"103","author":"Janus","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.kint.2019.04.043","article-title":"Summary of the International Conference on Onco-Nephrology: An emerging field in medicine","volume":"96","author":"Capasso","year":"2019","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute Kidney Injury in Patients with Cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: A Danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur. J. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2014Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit. Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/cc4915","article-title":"RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis","volume":"10","author":"Hoste","year":"2006","journal-title":"Crit. Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djy167","article-title":"Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study","volume":"111","author":"Kitchlu","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.ejrad.2011.08.005","article-title":"Role of combined DWIBS\/3D-CE-T1w whole-body MRI in tumor staging: Comparison with PET-CT","volume":"81","author":"Manenti","year":"2012","journal-title":"Eur. J. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/MCC.0b013e32830ef70b","article-title":"Acute renal problems in the critically ill cancer patient","volume":"14","author":"Lameire","year":"2008","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2215\/CJN.03530412","article-title":"Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center","volume":"8","author":"Salahudeen","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Meraz-Munoz, A., Langote, A., Jhaveri, K., Izzedine, H., and Gudsoorkar, P. (2021). Acute Kidney Injury in the Patient with Cancer. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040611"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"868715","DOI":"10.3389\/fcell.2022.868715","article-title":"Chronic Kidney Disease and Cancer: Inter-Relationships and Mechanisms","volume":"10","author":"Hu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.numecd.2009.01.009","article-title":"The usefulness of the prognostic inflammatory and nutritional index (PINI) in a haemodialysis population","volume":"19","author":"Dessi","year":"2009","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Noce, A., Bocedi, A., Campo, M., Marrone, G., Di Lauro, M., Cattani, G., Di Daniele, N., and Romani, A. (2020). A Pilot Study of a Natural Food Supplement as New Possible Therapeutic Approach in Chronic Kidney Disease Patients. Pharmaceuticals, 13.","DOI":"10.3390\/ph13070148"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tinti, F., Lai, S., Noce, A., Rotondi, S., Marrone, G., Mazzaferro, S., Di Daniele, N., and Mitterhofer, A.P. (2021). Chronic Kidney Disease as a Systemic Inflammatory Syndrome: Update on Mechanisms Involved and Potential Treatment. Life, 11.","DOI":"10.3390\/life11050419"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.phrs.2007.11.005","article-title":"Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome","volume":"57","author":"Noce","year":"2008","journal-title":"Pharmacol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00592-019-01413-7","article-title":"Hemodialysis biomarkers: Total advanced glycation end products (AGEs) against oxidized human serum albumin (HSAox)","volume":"56","author":"Noce","year":"2019","journal-title":"Acta Diabetol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Noce, A., Marrone, G., Di Daniele, F., Ottaviani, E., Wilson Jones, G., Bernini, R., Romani, A., and Rovella, V. (2019). Impact of Gut Microbiota Composition on Onset and Progression of Chronic Non-Communicable Diseases. Nutrients, 11.","DOI":"10.3390\/nu11051073"},{"key":"ref_26","first-page":"2057","article-title":"Link between gut microbiota dysbiosis and chronic kidney disease","volume":"26","author":"Noce","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_27","first-page":"e901308","article-title":"Gut Microbioma Population: An Indicator Really Sensible to Any Change in Age, Diet, Metabolic Syndrome, and Life-Style","volume":"2014","author":"Noce","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Merra, G., Noce, A., Marrone, G., Cintoni, M., Tarsitano, M.G., Capacci, A., and De Lorenzo, A. (2020). Influence of Mediterranean Diet on Human Gut Microbiota. Nutrients, 13.","DOI":"10.3390\/nu13010007"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/fampra\/cms079","article-title":"Chronic kidney disease, a useful trigger for proactive primary care? Mortality results from a large U.K. cohort","volume":"30","author":"Marks","year":"2013","journal-title":"Fam. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ciorcan, M., Chisavu, L., Mihaescu, A., Gadalean, F., Bob, F.R., Negru, S., Schiller, O.M., Grosu, I.D., Marc, L., and Chisavu, F. (2022). Chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0265930"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.amjhyper.2004.08.010","article-title":"Microalbuminuria and cardiovascular risk","volume":"17","author":"Karalliedde","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0959-8049(97)10003-X","article-title":"Microalbuminuria in patients with lung cancer","volume":"34","author":"Pedersen","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1365-2141.2003.04285.x","article-title":"Mediators of inflammation correlate with microalbuminuria in patients with non-Hodgkin\u2019s lymphoma","volume":"121","author":"Pedersen","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/028418600430699","article-title":"Increased urinary albumin excretion rate in breast cancer patients","volume":"39","author":"Pedersen","year":"2000","journal-title":"Acta Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2337\/diacare.18.4.572","article-title":"Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion","volume":"18","author":"Mogensen","year":"1995","journal-title":"Diabetes Care"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1681\/ASN.2007060712","article-title":"Association of albuminuria and cancer incidence","volume":"19","author":"Jorgensen","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.bbmt.2008.09.015","article-title":"Albuminuria in hematopoietic cell transplantation patients: Prevalence, clinical associations, and impact on survival","volume":"14","author":"Hingorani","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/02841869609084000","article-title":"Prevalence and prognostic significance of proteinuria in patients with lung cancer","volume":"35","author":"Pedersen","year":"1996","journal-title":"Acta Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2215\/CJN.09000819","article-title":"Screening for Cancer in Patients with Glomerular Diseases","volume":"15","author":"Plaisier","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-64-1-41","article-title":"The association of cancer and the nephrotic syndrome","volume":"64","author":"Lee","year":"1966","journal-title":"Ann. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1523-1755.1999.00548.x","article-title":"Paraneoplastic glomerulopathies: New insights into an old entity","volume":"56","author":"Ronco","year":"1999","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/sj.ki.5001790","article-title":"Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association","volume":"70","author":"Lefaucheur","year":"2006","journal-title":"Kidney Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ndt\/gfr534","article-title":"Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy","volume":"27","author":"Qu","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2008.08.003","article-title":"Paraneoplastic glomerular diseases and malignancies","volume":"70","author":"Bacchetta","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_46","first-page":"S75","article-title":"Membranous nephropathy: Pathophysiology and natural history","volume":"13","author":"Lambeau","year":"2017","journal-title":"Nephrol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40620-017-0451-5","article-title":"Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases","volume":"31","author":"Radice","year":"2018","journal-title":"J. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000520399","article-title":"Malignancy-Associated Membranous Nephropathy with Positive Anti-PLA2R Autoantibodies: Coincidence or Connection","volume":"11","author":"Baker","year":"2021","journal-title":"Case Rep. Nephrol. Dial."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ajkd.2007.06.003","article-title":"Long-term risk of cancer in membranous nephropathy patients","volume":"50","author":"Bjorneklett","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future","volume":"29","author":"Perazella","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000435808","article-title":"ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis Linked with Non-Small Cell Carcinoma of the Lung","volume":"5","author":"Baldeo","year":"2015","journal-title":"Case Rep. Nephrol. Dial."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1681\/ASN.V85848","article-title":"Nephrotic syndrome, renal failure, and renal malignancy: An unusual tumor-associated glomerulonephritis","volume":"8","author":"Ahmed","year":"1997","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000409763","article-title":"IgA mesangial nephropathy in neoplastic diseases","volume":"40","author":"Mustonen","year":"1984","journal-title":"Contrib. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000045388","article-title":"Renal cell carcinoma and paraneoplastic IgA nephropathy","volume":"82","author":"Magyarlaki","year":"1999","journal-title":"Nephron"},{"key":"ref_56","first-page":"38","article-title":"Tossicit\u00e0 renale da farmaci antineoplastici","volume":"S77","author":"Lepori","year":"2020","journal-title":"G. Ital. Di Nefrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: Renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ckj\/sfaa127","article-title":"Preventive strategies for acute kidney injury in cancer patients","volume":"14","author":"Cosmai","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2215\/CJN.02050309","article-title":"Renal vulnerability to drug toxicity","volume":"4","author":"Perazella","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_61","first-page":"32","article-title":"Vigilance Regarding Drug-Induced Acute Kidney Injury in Ambulatory Older Adults","volume":"45","author":"Zagaria","year":"2020","journal-title":"US Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Kwiatkowska, E., Domanski, L., Dziedziejko, V., Kajdy, A., Stefanska, K., and Kwiatkowski, S. (2021). The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116109"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ckj\/sft135","article-title":"Nephrotoxicity of recent anti-cancer agents","volume":"7","author":"Lameire","year":"2014","journal-title":"Clin. Kidney J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/1097-0142(19820501)49:9<1784::AID-CNCR2820490909>3.0.CO;2-6","article-title":"Acute nephrotoxicity following cis-dichlorodiammine-platinum","volume":"49","author":"Bitran","year":"1982","journal-title":"Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","article-title":"Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2","volume":"167","author":"Ciarimboli","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","article-title":"Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention\/therapy","volume":"30","author":"Perazella","year":"2010","journal-title":"Semin. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s002800050661","article-title":"Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods","volume":"40","author":"Stewart","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","article-title":"Renal effects of anti-angiogenesis therapy: Update for the internist","volume":"122","author":"Gurevich","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2215\/CJN.08111109","article-title":"Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor","volume":"5","author":"Robinson","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","article-title":"Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer","volume":"4","author":"Dine","year":"2017","journal-title":"Asia-Pac. J. Oncol. Nurs."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ahmad, A. (2020). CAR-T Cell Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124303"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(20)30540-7","article-title":"The link between kidney disease and cancer: Complications and treatment","volume":"396","author":"Malyszko","year":"2020","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2215\/CJN.08580719","article-title":"Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation","volume":"15","author":"Renaghan","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.ki.5000055","article-title":"Acute renal failure in hematopoietic cell transplantation","volume":"69","author":"Parikh","year":"2006","journal-title":"Kidney Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0272-6386(89)80054-X","article-title":"Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients","volume":"13","author":"Zager","year":"1989","journal-title":"Am. J. Kidney Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1046\/j.1523-1755.2002.00455.x","article-title":"Renal dysfunction in allogeneic hematopoietic cell transplantation","volume":"62","author":"Parikh","year":"2002","journal-title":"Kidney Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1053\/j.ajkd.2004.11.013","article-title":"Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation","volume":"45","author":"Parikh","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bmt.2009.99","article-title":"A multicenter, retrospective study of acute kidney injury in adult patients with nonmyeloablative hematopoietic SCT","volume":"45","author":"Liu","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbmt.2008.10.011","article-title":"Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience","volume":"15","author":"Pinana","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal Complications of Hematopoietic-Cell Transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.semnephrol.2010.09.009","article-title":"Acute kidney injury in hematopoietic cell transplantation","volume":"30","author":"Kogon","year":"2010","journal-title":"Semin. Nephrol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2215\/CJN.00150118","article-title":"Pharmacology behind Common Drug Nephrotoxicities","volume":"13","author":"Perazella","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: Incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ki.1994.417","article-title":"Acute renal failure in the setting of bone marrow transplantation","volume":"46","author":"Zager","year":"1994","journal-title":"Kidney Int."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2018.06.013","article-title":"Emerging Concepts in Hematopoietic Stem Cell Transplantation-Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments","volume":"72","author":"Wanchoo","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/sj.bmt.1705573","article-title":"Chronic kidney disease in long-term survivors of hematopoietic cell transplant","volume":"39","author":"Hingorani","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ijrobp.2006.02.021","article-title":"Renal dysfunction after total body irradiation: Dose-effect relationship","volume":"65","author":"Kal","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/j.1600-6143.2008.02408.x","article-title":"Chronic kidney disease after hematopoietic cell transplantation: A systematic review","volume":"8","author":"Ellis","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/sj.bmt.1705643","article-title":"Significant increase in end-stage renal disease after hematopoietic stem cell transplantation","volume":"39","author":"Cohen","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2215\/CJN.10630917","article-title":"Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study","volume":"13","author":"Hingorani","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/j.ajkd.2012.09.020","article-title":"Kidney complications of hematopoietic stem cell transplantation","volume":"61","author":"Singh","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1681\/ASN.2004100843","article-title":"Renal failure associated with cancer and its treatment: An update","volume":"16","author":"Humphreys","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","article-title":"The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology","volume":"11","author":"Xu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2169\/internalmedicine.9838-17","article-title":"An Overview of Kidney Disease Following Hematopoietic Cell Transplantation","volume":"57","author":"Ando","year":"2018","journal-title":"Intern. Med."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Musial, K., Kalwak, K., and Zwolinska, D. (2021). The Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Kidney Function in Children-A Single Center Experience. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051113"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"87","DOI":"10.17219\/acem\/130355","article-title":"The incidence of acute kidney injury in children undergoing allogenic hematopoietic stem cell transplantation: A pilot study","volume":"30","author":"Augustynowicz","year":"2021","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron. Clin. Pract."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.01900214","article-title":"AKI in hospitalized children: Comparing the pRIFLE, AKIN, and KDIGO definitions","volume":"10","author":"Sutherland","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.17219\/acem\/101573","article-title":"Markers of acute kidney injury in children undergoing hematopoietic stem cell transplantation","volume":"28","author":"Augustynowicz","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.anndiagpath.2005.09.015","article-title":"Acute renal failure caused by renal infiltration by hematolymphoid malignancy","volume":"10","author":"Lommatzsch","year":"2006","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5492\/wjccm.v4.i2.130","article-title":"Tumor lysis syndrome: A clinical review","volume":"4","author":"Mirrakhimov","year":"2015","journal-title":"World J. Crit. Care Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/OTT.S103864","article-title":"Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase","volume":"10","author":"Alakel","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/01.ASN.0000017575.50319.77","article-title":"Downregulation of intestinal cytochrome p450 in chronic renal failure","volume":"13","author":"Leblond","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_110","first-page":"54","article-title":"Renal organic acid transport: Uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia","volume":"263","author":"Henderson","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/clpt.2009.163","article-title":"The influence of chronic renal failure on drug metabolism and transport","volume":"86","author":"Dreisbach","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: A prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J. Cancer. Res. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.10.025","article-title":"Creatinine: From physiology to clinical application","volume":"72","author":"Kashani","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2215\/CJN.11721018","article-title":"Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing","volume":"14","author":"Casal","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.ackd.2017.10.003","article-title":"Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning","volume":"25","author":"Hudson","year":"2018","journal-title":"Adv. Chronic. Kidney Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/annonc\/mdm011","article-title":"Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations","volume":"18","author":"Chatelut","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_118","first-page":"7169897","article-title":"Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function","volume":"2018","author":"Barreto","year":"2018","journal-title":"Case Rep. Hematol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","article-title":"New Model for Estimating Glomerular Filtration Rate in Patients With Cancer","volume":"35","author":"Janowitz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"11219","DOI":"10.1038\/s41598-020-68010-5","article-title":"Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy","volume":"10","author":"Klockl","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.6004\/jnccn.2021.0043","article-title":"NCCN Guidelines(R) Insights: Older Adult Oncology, Version 1.2021","volume":"19","author":"Dotan","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"66","DOI":"10.6004\/jnccn.2018.0001","article-title":"Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Coccia","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2006.11.004","article-title":"International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency","volume":"43","author":"Lichtman","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2020.03.026","article-title":"How to determine kidney function in cancer patients?","volume":"132","author":"Sprangers","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"141","DOI":"10.34067\/KID.0000952019","article-title":"GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer","volume":"1","author":"McMahon","year":"2020","journal-title":"Kidney360"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"104417","DOI":"10.1016\/j.yrtph.2019.104417","article-title":"Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate","volume":"107","author":"Dorshow","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2018.08.019","article-title":"A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials","volume":"104","author":"Ang","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/j.ackd.2013.05.005","article-title":"Electrolyte disorders associated with cancer","volume":"21","author":"Rosner","year":"2014","journal-title":"Adv. Chronic. Kidney Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2016.02.064","article-title":"Electrolyte disorders associated with the use of anticancer drugs","volume":"777","author":"Liamis","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0889-8588(05)70126-X","article-title":"Acquired Fanconi\u2019s syndrome associated with monoclonal gammopathies","volume":"13","author":"Lacy","year":"1999","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/17474086.2016.1127156","article-title":"Tumor lysis syndrome: Review of pathogenesis, risk factors and management of a medical emergency","volume":"9","author":"Criscuolo","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s11739-018-1898-7","article-title":"Extreme hypomagnesemia: Characteristics of 119 consecutive inpatients","volume":"13","author":"Cheminet","year":"2018","journal-title":"Intern. Emerg. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"11294","DOI":"10.1073\/pnas.1203129109","article-title":"Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity","volume":"109","author":"Sengupta","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Noce, A., Marrone, G., Ottaviani, E., Guerriero, C., Di Daniele, F., Pietroboni Zaitseva, A., and Di Daniele, N. (2021). Uremic Sarcopenia and Its Possible Nutritional Approach. Nutrients, 13.","DOI":"10.3390\/nu13010147"},{"key":"ref_138","first-page":"72","article-title":"Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: Laboratory and clinical aspects","volume":"26","author":"Capizzi","year":"1999","journal-title":"Semin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/jpet.104.075119","article-title":"The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway","volume":"312","author":"Wu","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0272-6386(86)80112-3","article-title":"Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity","volume":"8","author":"Ries","year":"1986","journal-title":"Am. J. Kidney Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ki.1993.173","article-title":"Glycine reduces early renal parenchymal uptake of cisplatin","volume":"43","author":"Heyman","year":"1993","journal-title":"Kidney Int."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1681\/ASN.2004030225","article-title":"Nephroprotection by theophylline in patients with cisplatin chemotherapy: A randomized, single-blinded, placebo-controlled trial","volume":"16","author":"Benoehr","year":"2005","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2254\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:14:35Z","timestamp":1760123675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/8\/2254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":142,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15082254"],"URL":"https:\/\/doi.org\/10.3390\/cancers15082254","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]}}}